Factor 8 SHL denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for factor 8 shl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Factor VIII (SHL) as Duplicate Therapy

Blue Cross Blue Shield's duplicate-therapy denial means their system flagged that another clotting-factor product is already active on your benefit record — or that you recently received a different Factor VIII formulation — and their policy treats simultaneous or overlapping factor replacement as redundant.

This denial is almost always appealable, because extended half-life (SHL) Factor VIII products are clinically and pharmacokinetically distinct from standard half-life formulations. Your prescriber can document why the specific product is not a true therapeutic duplicate.

## Federal Appeal Rights

• ERISA §503 (employer-sponsored plans): you have the right to a full-and-fair internal review, followed by an independent external review.
• ACA §2719 (most non-grandfathered plans): you have access to an independent external review through an accredited Independent Review Organization (IRO). You generally have approximately four months from the denial notice to request external review.
• Expedited review: if your hematologist documents that a standard 30-day timeline would seriously jeopardize your health, request expedited internal and external review simultaneously.

## Concrete Appeal Timeline

1. File the internal appeal within the timeframe printed on your Explanation of Benefits (EOB). 2. If upheld, request external review immediately — do not wait. 3. Track every submission date; insurers are bound by federal response deadlines.

## Documentation to Gather

• Diagnosis confirmation: hematology records establishing your specific hemophilia A diagnosis and inhibitor status (if applicable).
• Pharmacokinetic (PK) justification: if your prescriber performed individual PK profiling, include those results — they directly distinguish SHL from standard half-life products.
• Prior-treatment history: dates and outcomes on any previous Factor VIII product, including breakthrough bleeds, annualized bleed rates, and adherence challenges.
• Prescriber medical-necessity letter: the letter should explicitly address why this is not a duplicate — citing the distinct half-life profile, your dosing schedule, and the treating hematologist's clinical rationale.
• Clinical severity documentation: joint damage imaging, pain scores, missed school/work records, emergency or infusion-center visits.

## Criteria-Mapping Structure

Copy each requirement from BCBS's published Coverage Medical Policy for Factor VIII products. For each criterion, provide the specific chart fact that satisfies it. For example:

| Policy Requirement | Your Chart Evidence | |---|---| | Confirmed hemophilia A diagnosis | [Date of diagnosis, FVIII activity level per your lab record] | | Prescribing by a qualified hematologist | [Name and credentials of treating hematologist] | | Distinction from concurrent active benefit | [Explanation why prior authorization for different product does not cover this SHL formulation] |

Obtain the exact current eligibility criteria from BCBS's published medical policy for Factor VIII/extended half-life clotting factors and from the FDA-approved prescribing information for the specific product. Do not rely on any third-party summary — policies change, and your appeal must match the criteria in force at the time of your denial.